MX2024011346A - Compuestos inhibidores de la interaccion proteina-proteina de mll1-wdr5 de cruce de la barrera hematoencefalica y usos de estos - Google Patents
Compuestos inhibidores de la interaccion proteina-proteina de mll1-wdr5 de cruce de la barrera hematoencefalica y usos de estosInfo
- Publication number
- MX2024011346A MX2024011346A MX2024011346A MX2024011346A MX2024011346A MX 2024011346 A MX2024011346 A MX 2024011346A MX 2024011346 A MX2024011346 A MX 2024011346A MX 2024011346 A MX2024011346 A MX 2024011346A MX 2024011346 A MX2024011346 A MX 2024011346A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- mll1
- blood
- brain barrier
- inhibitor compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000004850 protein–protein interaction Effects 0.000 title abstract 2
- 230000008499 blood brain barrier function Effects 0.000 title 1
- 210000001218 blood-brain barrier Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- LUEYUHCBBXWTQT-UHFFFAOYSA-N 4-phenyl-2h-triazole Chemical compound C1=NNN=C1C1=CC=CC=C1 LUEYUHCBBXWTQT-UHFFFAOYSA-N 0.000 abstract 2
- 150000001448 anilines Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263319589P | 2022-03-14 | 2022-03-14 | |
| PCT/US2023/015021 WO2023177592A1 (en) | 2022-03-14 | 2023-03-10 | Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011346A true MX2024011346A (es) | 2025-01-09 |
Family
ID=88024124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011346A MX2024011346A (es) | 2022-03-14 | 2024-09-13 | Compuestos inhibidores de la interaccion proteina-proteina de mll1-wdr5 de cruce de la barrera hematoencefalica y usos de estos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230293539A1 (https=) |
| EP (1) | EP4493184A4 (https=) |
| JP (1) | JP2025509830A (https=) |
| KR (1) | KR20250009417A (https=) |
| CA (1) | CA3245866A1 (https=) |
| MX (1) | MX2024011346A (https=) |
| WO (1) | WO2023177592A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025090881A1 (en) * | 2023-10-27 | 2025-05-01 | Huyabio International, Llc | Combination therapies of wdr5 inhibitors and pd-1 inhibitors |
| WO2026058961A1 (en) | 2024-09-13 | 2026-03-19 | Alivexis, Inc. | Wdr5 inhibitors, compounds, pharmaceutical compositions, and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8063058B2 (en) * | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
| US11319299B2 (en) * | 2016-03-01 | 2022-05-03 | Propellon Therapeutics Inc. | Substituted carboxamides as inhibitors of WDR5 protein-protein binding |
| CN107382840B (zh) * | 2016-05-16 | 2020-09-01 | 四川大学 | 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途 |
| WO2019046944A1 (en) * | 2017-09-06 | 2019-03-14 | Propellon Therapeutics Inc. | INHIBITORS OF PROTEIN BINDING WDR5-PROTEIN |
| CN108715585A (zh) * | 2018-04-23 | 2018-10-30 | 中国药科大学 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
| EP4523755A3 (en) * | 2018-09-18 | 2025-06-11 | F. Hoffmann-La Roche AG | Quinazoline derivatives as antitumor agents |
| CN109734674B (zh) * | 2019-02-26 | 2022-08-26 | 中国药科大学 | 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途 |
| TWI899080B (zh) * | 2019-05-27 | 2025-10-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｄｎａ依賴性蛋白激酶抑制劑 |
-
2023
- 2023-03-10 CA CA3245866A patent/CA3245866A1/en active Pending
- 2023-03-10 KR KR1020247034049A patent/KR20250009417A/ko active Pending
- 2023-03-10 WO PCT/US2023/015021 patent/WO2023177592A1/en not_active Ceased
- 2023-03-10 US US18/120,311 patent/US20230293539A1/en active Pending
- 2023-03-10 JP JP2024555344A patent/JP2025509830A/ja active Pending
- 2023-03-10 EP EP23771268.2A patent/EP4493184A4/en active Pending
-
2024
- 2024-09-13 MX MX2024011346A patent/MX2024011346A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250009417A (ko) | 2025-01-17 |
| CA3245866A1 (en) | 2023-09-21 |
| WO2023177592A1 (en) | 2023-09-21 |
| JP2025509830A (ja) | 2025-04-11 |
| EP4493184A1 (en) | 2025-01-22 |
| EP4493184A4 (en) | 2026-03-18 |
| US20230293539A1 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024011346A (es) | Compuestos inhibidores de la interaccion proteina-proteina de mll1-wdr5 de cruce de la barrera hematoencefalica y usos de estos | |
| WO2022221528A3 (en) | Kras g12c inhibitors | |
| MX2025003398A (es) | Nuevo compuesto tetraheterociclico | |
| ZA202209563B (en) | Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors | |
| PH12022551503A1 (en) | Kras mutant protein inhibitors | |
| EP4477220A3 (en) | Plasma kallikrein inhibitors and uses thereof | |
| PH12022550469A1 (en) | Kras g12d inhibitors | |
| MX2024003922A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos. | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| ECSP045126A (es) | INHIBIDORES DEL FACTOR Xa Y DE OTRAS PROTEASAS DE SERINA IMPLICADAS EN LA CASCADA DE LA COAGULACIÓN | |
| WO2003065987A3 (en) | Granzyme b inhibitors | |
| EA200900613A1 (ru) | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз | |
| MX2023011014A (es) | Inhibidores de heteroarílo de la calicreína plasmática. | |
| CR10636A (es) | Inhibidor de quinasa | |
| MX2025008920A (es) | Inhibidores de parp1 triciclicos y usos de estos | |
| JOP20220290A1 (ar) | مثبطات إنزيم الجلوكوسيل سيراميداز غير المتعلقة بالجسيم الحال واستخدامتها | |
| BR112022003584A2 (pt) | Compostos de pirrolopirimidina inibidores de perk | |
| MX2022014007A (es) | Compuestos como inhibidores de bcl-2. | |
| MX2024011348A (es) | Inhibidor de la interacción proteína-proteína mll1-wdr5 de feniltriazol. | |
| JOP20230091A1 (ar) | مثبط magl | |
| JOP20220291A1 (ar) | مثبطات جلوكوزيل سيراميدز غير متعلقة بالجسم الحال واستخداماتها | |
| MX2025003571A (es) | Inhibidores de tead y metodos de uso de los mismos | |
| MX2025003568A (es) | Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap) | |
| DE60329326D1 (de) | Tace inhibitoren | |
| MX2024011347A (es) | Inhibidor de la interaccion proteina-proteina mll1-wdr5 haloalquilpiridiltriazol |